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A B S T R A C T
Objective: Treatment of status epilepticus (SE) has not changed in the last few decades, benzodiazepines
plus phenytoin or valproate being the most common treatment. Once this ﬁrst and second line treatment
has failed SE is considered refractory (RSE). This study aimed to assess the efﬁcacy and tolerability of
intravenous (iv) lacosamide (LCM) in RSE.
Method: Patients with RSE who were treated with ivLCM in six Spanish centers were prospectively
included. Efﬁcacy was deﬁned as cessation of seizures after starting ivLCM, with no need for any further
antiepileptic drug. All patients had been unsuccessfully treated following the standard protocol
(benzodiazepines plus phenytoin or valproate) before ivLCM was added.
Results: Thirty-four patients were included, 52.9% men, with mean age of 60.15 years. In 58.9% of
patients the etiology was symptomatic, and the most common type of SE was focal convulsive (82.4%).
Mean initial bolus dose of LCM was 323.53 mg. ivLCM was effective in more than half of patients (64.7%),
with termination of SE before 12 h in 50% of them. ivLCM was used as a fourth or later option in 76.5% of
patients. No serious adverse events attributable to LCM were reported.
Conclusions: LCM might be a fast, effective and safe add-on treatment in RSE.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is a neurological emergency, associated
with signiﬁcant morbidity and mortality, which requires early
recognition and treatment. Treatment of SE has not changed in the
last few decades. Currently, benzodiazepine (BZD) (lorazepam or
diazepam) followed by phenytoin (PHT) is still considered the
most effective treatment in the majority of the guidelines,1,2 with
an efﬁcacy of 70%.3 All these guidelines follow the Treiman
Veterans Study conducted in 1998 in which no differences were
observed between treatment with lorazepam alone, diazepam
plus PHT, and phenobarbital alone, whereas PHT alone was less
effective.4 Nowadays the use of benzodiazepines followed by* Corresponding author at: Hospital Universitari de Bellvitge, c/Feixa Llarga sn,
Hospitalet de Llobregat, 08907 Barcelona, Spain.
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http://dx.doi.org/10.1016/j.seizure.2012.10.004valproate is also licensed in a few countries for this purpose5
because some randomized case–control studies have found
efﬁcacy similar to phenytoin and valproate administered after
benzodiazepines.6
Once ﬁrst- and second-line treatments have failed, SE is
considered refractory (RSE); this occurs in 9–31% of patients with
status epilepticus.7 In refractory generalized tonic-clonic SE,
aggressive treatment, including coma with anesthetic drugs, is
usually necessary.1,2 The use of other antiepileptic drugs (AED)
prior to the induction of pharmacological anesthesia should be
considered in older patients, patients with comorbidities, and,
particularly, patients with other types of SE. In this context
intravenous (iv) levetiracetam (LEV) used as third- or greater line
treatment has shown efﬁcacy of 50–60% in several case series,8
even though it seems roughly as effective as benzodiazepines
when it is used as ﬁrst-line treatment.9 However, it appears
possibly less effective compared to VPA or PHT in controlling SE
after benzodiazepines.10vier Ltd. All rights reserved.
Table 1
Demographic data of patients who received intravenous lacosamide for treatment
of status epilepticus.
Total %
Number of patients 34
Men/women 18/16 52.9/47.1
Mean age (years) (range) 60.15 (22–86)
Comorbidity 26 76.5
Previous history of epilepsy 16 47.1
Type of SE
FMSE 28 82.4
Simple 7 20.6
Complex 21 61.8
NCSE 5 14.7
GCSE 1 2.8
Etiology
Symptomatic 20 58.9
Acute Symptomatic 11 32.4
Remote symptomatic 9 26.5
Forgotten or suppression of AED 5 14.7
Cryptogenic 2 5.9
Tumoral 1 2.9
Others 6 17.3
Ictal EEG 32 94.1
LCM, lacosamide: SE, status epilepticus; FMSE, focal motor status epilepticus; NCSE,
non-convulsive status epilepticus; GCSE, generalized convulsive status epileticus;
AED, anti-epileptic drugs.
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Administration as an adjunctive therapy for partial onset seizures
in patients with epilepsy aged 17 and older (United States). Some
case reports and case series have shown encouraging results with
ivLCM in SE.11–14
We report the effectiveness, safety and role of LCM in patients
with SE treated with ivLCM when ﬁrst- and second-line AEDs have
failed. In contrast to other published series, LCM was always
added as a third or subsequent drug (after benzodiazepines and at
least one traditional AED). Generally accepted guidelines were
followed at all times and no changes in the usual clinical practice
were made.
2. Methods
We prospectively identiﬁed patients diagnosed with SE who
received ivLCM at six Spanish Hospitals: Hospital Universitari de
Bellvitge, Hospital Universitario La Fe, Hospital Vall d’Hebro´n,
Hospital General de Granollers, Hospital Povisa, and Hospital
Virgen de las Nieves. All patients received at least one dose of
ivLCM for treatment of SE between September 2010 and March
2012. All included patients were treated following a standard
protocol (BZD plus PHT and/or VPA, and in many cases LEV), so LCM
was always used as add-on therapy in the treatment of established
SE refractory to usual agents or when were contraindicated.
Patient medical charts were carefully completed regarding
electrophysiological data, seizure type, etiology, onset and
duration of SE, order in which AEDs were administered, doses of
ivLCM and concomitant AEDs, tolerability, and outcome. A
standardized data sheet was used for documentation in all
participating centers.
The following contraindications were considered in this
standard protocol: BZDs were contraindicated in respiratory
failure and Lennox–Gastaut syndrome; PHT was contraindicated
in hepatic failure, allergy, disorders of heart rhythm and important
unpredictable pharmacological interaction; and VPA was contra-
indicated in hepatic failure and thrombocytopenia.
Patients with whom the standard protocol was not followed
were excluded. Anoxic myoclonic SE patients (because of the
implicit poor prognosis) were excluded.
SE was diagnosed according to the ILAE deﬁnition: (1) any
seizure lasting for 30 min or longer or (2) intermittent seizures
repeating within 30 min without full recuperation of conscious-
ness. SEs were classiﬁed according to their semiology and with EEG
support into generalized convulsive SE, focal motor SE (including
epilepsia partialis continua, EPC) or non-convulsive SE. Cessation
of SE was deﬁned as disappearance of EEG status-seizure activity
(all patients with the diagnosis of NCSE were monitored with
continuous EEG monitoring) or disappearance of previous ictal
symptoms without any suspicion of ongoing subclinical seizure
activity, if conﬁrmed by a subsequent EEG recording. We
considered SE controlled if no change in antiepileptic medication
was needed for at least 48 h after clinical or electrographic
resolution. The last antiepileptic drug (AED) administered before
SE cessation was deﬁned as effective or termination drug. The
study was approved by the local ethical committee. Consent
procedures were established by local ethical committee regulation
for patients who required emergency treatment.
3. Results
Thirty-four patients (52.9% men) aged between 22 and 86 years
with refractory SE (RSE) were included in the study. SE was the
initial presentation in 52.9% (18) patients, and in 58.9% (20)
patients the etiology was symptomatic. In 82.4% (28) patients the
SE was focal motor SE (FMSE), and in 14.7% (5) non-convulsive SE(NCSE); in only in 2.8% (1) was it generalized convulsive SE (GCSE).
An ictal EEG previous to LCM treatment was carried out on all but
two patients. Demographic data are presented in Table 1.
The median interval from SE onset to the start of SE therapy
was 0.3–240 h (median 4.5 h). All but ﬁve patients received
benzodiazepines as ﬁrst-line treatment. BZDs were contra-
indicated in a patient with Lennox–Gastaut syndrome and 4
patients with severe respiratory diseases. All received PHT or
VPA as ﬁrst- or second-line treatment (29 as second-line). PHT
was contraindicated in 1 patient due to allergy, 6 due to
important pharmacological interactions, 1 due to acute auricular
ﬁbrillation, and 2 due to auricular–ventricular block. VPA was
contraindicated in 6 patients due to severe hepatopathy. All but
4 patients received LEV (contraindicated due to severe renal
disease). LCM was used as a fourth or later option in 26 patients
(76.5%). LCM was started after a median interval latency of 1.0–
250 h (median 48.0 h). The ﬁrst LCM bolus was 400 mg in 17
patients (50%), 300 in 9 (26.5%), 200 in 7 (20.6%), and 100 in 1
(2.9%). For 22 (64.7%) patients LCM terminated the SE, and in 17
of them, SE ceased within 12 h after the ﬁrst administration of
LCM (9 patients before 60 min after ivLCM loading dose). In 12
patients, further AED therapy or anesthesia was required. Oral or
IV LCM as an adjunct AED, range 100–600 mg (mean 323.53 mg),
was maintained in most of these patients. In 3 patients (8.8%) SE
could not be terminated. SE termination was conﬁrmed by EEG
in all NCSE (Table 2).
All adverse events were mild in intensity, and they were
observed in only 2 patients (5.9%). One of these reported diplopia
while the other patient presented confused state and nystagmus.
In both patients the symptomatology was resolved by LCM dose
reduction. There were no patients who required LCM discontin-
uation. Seven patients died (20.6%) during the month following
due to acute illness (infection, stroke, etc.) or complications
related to the SE.
4. Discussion
There are some data in rat models for self-sustaining status
epilepticus (SSSE), with LCM reducing cumulative SSSE duration
and neuronal hippocampal damage and preventing spontaneous
recurrent seizures.15 However, there are no large, adequately
Table 2
Treatment parameters and outcomes.
Total LCM third/fourth LCM ﬁfth or later
34 18 (52.9%) 16 (47.1%)
LCM efﬁcacy 22 (64.7%) 13 (72.2%) 9 (56.3%)
Latency (h) onset SE–SE therapy
Median (range) 4.5 (0.3–240) 12.0 (1.0–144) 1.0 (0.3–240)
Latency (h) onset SE–LCM
Median (range) 48.0 (1.0–250) 60.0 (6.0–168) 48.0 (1.0–250)
Treatment before LCM
Benzodiazepines 29 13 16
Phenytoin 24 8 16
Valproic acid 28 13 15
Levetiracetam 30 14 16
Anesthesia 1 0 1
LCM dose (mean, range) 323.53 (100–400) 322.22 (100–400) 325.00 (200–400)
Mean initial bolus (mg) 323.53 (100–600) 355.56 (100–600) 287.50 (100–400)
Mean daily dose (mg)
Termination of SE by LCM iv
<12 h after LCM iv 17 (50%) 9 (50%) 8 (50%)
>12 to <48 h after LCM iv 5 (14.7%) 4 (22.2%) 1 (6.3%)
Further AED therapy needed 12 (35.3%) 5 (27.8%) 7 (43.7%)
Outcome 31 (91.2%) 18 (100%) 13 (81.3%)
Termination of SE 3 (8.8%) 0 3 (18.7%)
No termination of SE
LCM, lacosamide; SE, status epilepticus; iv, intravenous; AED, anti-epileptic drugs.
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in patients with SE. Nevertheless, some previously published
retrospective series have observed efﬁcacy rates of 70% or more
when LCMs are used in SE patient treatment for both refractory and
non-refractory SE.12–14
Although refractory SE is known to be more resistant to
treatment, with a worse prognosis with each unsuccessful
attempt to treat, 64.7% of RSE patients in this study demon-
strated response to LCM treatment. In the context of super-
refractory SE, which many of these cases were, intravenous LCM
also seems to be fast, with most patients responding in the ﬁrst
12 h after ivLCM administration. This response was achieved
with a loading dose between 200 and 400 mg ivLCM. This is in
line with the recently referred published data, but in contrast, in
the present study LCM was always added as a third or later drug
(benzodiazepines and at least one traditional AED) following the
generally accepted guidelines. In previous studies only Kellin-
ghaus et al.11 and Ho¨ﬂer et al.13 performed a subgroup analysis
concerning the time at which LCM was administered. No serious
adverse side effects or drug–drug interactions were seen in these
acutely ill patients.
In summary, our study data suggest that ivLCM can be an
effective add-on treatment, if standard drugs fail or are
unsuitable. However, the scope of the results is limited due to
the small sample size and lack of randomization. Nevertheless,
this is the largest series after Kellinghaus et al.,11 with 39
patients with SE, and the ﬁrst with prospective follow-up. The
management of patients with SE is challenging and there is a
paucity of data to guide treatment. We clearly need large,
adequately powered, randomized, actively controlled trials to
evaluate the efﬁcacy of ivLCM and other AEDs. Expert opinion
and guidelines may lend support to the treating physician, when
drugs are used off label, but quite obviously this cannot replace
randomized controlled studies.
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